Leukocytoclastic vasculitis during treatment with the oral EGFR tyrosine kinase inhibitor erlotinib

Ann Oncol. 2007 Sep;18(9):1582-3. doi: 10.1093/annonc/mdm420.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma / drug therapy
  • Administration, Oral
  • Aged
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / adverse effects*
  • Carcinoma, Hepatocellular / drug therapy
  • Erlotinib Hydrochloride
  • Female
  • Humans
  • Leg
  • Liver Neoplasms / drug therapy
  • Male
  • Middle Aged
  • Pancreatic Neoplasms / drug therapy
  • Quinazolines / administration & dosage
  • Quinazolines / adverse effects*
  • Vasculitis, Leukocytoclastic, Cutaneous / chemically induced*

Substances

  • Antineoplastic Agents
  • Quinazolines
  • Erlotinib Hydrochloride